4.8 Article

Treatment of murine lupus with cDNA encoding IFN-γR/Fc

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 106, 期 2, 页码 207-215

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI10167

关键词

-

资金

  1. NIAMS NIH HHS [AR39555, R37 AR039555, R01 AR031203, AR31203, R01 AR039555] Funding Source: Medline
  2. NIA NIH HHS [AG15061, T32 AG000080] Funding Source: Medline

向作者/读者索取更多资源

IFN-gamma, a pleiotropic cytokine, is a key effector molecule in the pathogenesis of several autoimmune diseases, including lupus. Importantly, deletion of IFN-gamma or IFN-gamma R in several lupus-predisposed mouse strains resulted in significant disease reduction, suggesting the potential for therapeutic intervention. We evaluated whether intramuscular injections of plasmids with cDNA encoding IFN-gamma R/Fc can retard lupus development and progression in MRL-Fas(lpr) mice. Therapy significantly reduced serum levels of IFN-gamma, as well as disease manifestations (autoantibodies, lymphoid hyperplasia, glomerulonephritis, mortality), when treatment was initiated at the predisease stage, particularly when IFN-gamma R/Fc expression was enhanced by electroporation at the injection site. Remarkably, disease was arrested and even ameliorated when this treatment was initiated at an advanced stage. This therapy represents a rare example of disease reversal and makes application of this nonviral gene therapy in humans with lupus (and perhaps other autoimmune/inflammatory conditions) highly promising.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据